Neoadjuvant Therapy

"Neoadjuvant Therapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, immunotherapy, hyperthermia, etc.) that precedes a necessary second modality of treatment.

Descriptor ID	D020360
MeSH Number(s)	E02.186.450
Concept/Terms	Neoadjuvant Therapy Neoadjuvant Therapy Neoadjuvant Therapies Therapies, Neoadjuvant Therapy, Neoadjuvant Neoadjuvant Treatment Neoadjuvant Treatments Treatment, Neoadjuvant Treatments, Neoadjuvant

Below are MeSH descriptors whose meaning is more general than "Neoadjuvant Therapy".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Therapeutics [E02]
Combined Modality Therapy [E02.186]
Neoadjuvant Therapy [E02.186.450]

Below are MeSH descriptors whose meaning is related to "Neoadjuvant Therapy".

Below are MeSH descriptors whose meaning is more specific than "Neoadjuvant Therapy".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Neoadjuvant Therapy" by people in this website by year, and whether "Neoadjuvant Therapy" was a major or minor topic of these publications.

Bar chart showing 83 publications over 22 distinct years, with a maximum of 8 publications in 2022

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2002	1	0	1
2005	0	1	1
2007	1	2	3
2008	0	3	3
2009	0	1	1
2010	1	2	3
2011	2	2	4
2012	1	3	4
2013	3	1	4
2014	1	2	3
2015	0	1	1
2016	2	0	2
2017	1	2	3
2018	1	4	5
2019	1	6	7
2020	1	3	4
2021	6	1	7
2022	2	6	8
2023	0	6	6
2024	5	0	5
2025	3	3	6
2026	2	0	2

Below are the most recent publications written about "Neoadjuvant Therapy" by people in Profiles.

Reddington H, Emmerick I, Diaz Collante J, Maini A, Kanzaria R, Crawford A, Phillips W, Maxfield M, Uy K, Lou F. Survival following sublobar resection after neoadjuvant therapy for T1N1-2M0 lung cancer. PLoS One. 2026; 21(6):e0349231.

View in: PubMed
Masanam MK, Bellon JR, Leone JP, Mittendorf EA, King TA, Kantor O. Breast-Conserving Therapy for Multiple Ipsilateral Breast Cancer After Neoadjuvant Systemic Therapy. Ann Surg Oncol. 2026 Apr; 33(4):3355-3363.

View in: PubMed
Boysen M, Lai SH, Byers S, Widmar M, Loria A, Russell T, Abelson JS, Fleming FJ, Monson JR, Vogel JD. Rectal Cancer Watch-and-Wait Management of Patients With Tumors Within Versus Beyond the Reach of Digital Rectal Examination. Ann Surg Oncol. 2026 Apr; 33(4):2856-2864.

View in: PubMed
Connolly JG, McCullum JC, Munroe C, Gaetani RS, Bliggenstorfer JT, Saraidaridis JT, Kuhnen AH, Marcello PW, Kleiman DA, Abelson JS. Circumferential Rectal Cancer Is a Risk Factor for Stricture Formation and Restaging Uncertainties After Neoadjuvant Therapy. Dis Colon Rectum. 2026 02 01; 69(2):181-190.

View in: PubMed
Sheedy SP, Arya S, Baheti AD, Chang KJ, Gollub MJ, El Homsi M, Kassam Z, Khatri G, Kim DH, Lalani T, Lee S, Nougaret S, Paroder V, Rauch GM, Wasnik AP, Weiser MR, Horvat N. SAR Disease-focused Panel: Restaging Rectal Cancer MRI Synoptic Report-User Guide with Imaging Review. Radiographics. 2025 11; 45(11):e250006.

View in: PubMed
Gaetani RS, Sharma S, Rizvi TZ, Abelson JS. Quality of Life and Functional Outcomes After Watch-and-Wait for Locally Advanced Rectal Cancer: A Meta-analysis. J Surg Res. 2025 11; 315:362-375.

View in: PubMed
Donovan KF, Tomada EP, Carmichael H, Ricardo A, Berger N, Bonaccorso A, Alavi K, Zaghiyan K, Pigazzi A, Sands D, DeBeche-Adams T, Chadi SA, McLemore EC, Marks JH, Maykel JA, Shawki SF, Steele SR, Albert M, Whiteford MH, Wexner SD, Sylla P. Impact of neoadjuvant treatment on functional outcomes after transanal total mesorectal excision (taTME)-a case series. Surg Endosc. 2025 Oct; 39(10):6802-6812.

View in: PubMed
Wolf DM, Yau C, Campbell M, Glas A, Barcaru A, Mittempergher L, Kuilman M, Brown-Swigart L, Hirst G, Basu A, Magbanua M, Sayaman R, Huppert L, Delson A, Symmans WF, Borowsky A, Pohlmann P, Rugo H, Clark A, Yee D, DeMichele A, Perlmutter J, Petricoin EF, Chien J, Stringer-Reasor E, Shatsky R, Liu M, Han H, Soliman H, Isaacs C, Nanda R, Hylton N, Pusztai L, Esserman L, van 't Veer L. Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial. JCO Precis Oncol. 2025 Jun; 9:e2400776.

View in: PubMed
Campbell MJ, Wolf DM, Yau C, Brown-Swigart L, Wulfkuhle J, Gallagher IR, Zhu Z, Bolen J, Vandenberg S, Hoyt C, Mori H, Borowsky A, Sit L, Perlmutter J, Asare SM, Nanda R, Liu MC, Yee D, DeMichele AM, Hylton NM, Pusztai L, Berry DA, Hirst GL, Petricoin EF, Veer LV, Esserman L. Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer. Cell Rep Med. 2024 Nov 19; 5(11):101799.

View in: PubMed
Davar D, Morrison RM, Dzutsev AK, Karunamurthy A, Chauvin JM, Amatore F, Deutsch JS, Das Neves RX, Rodrigues RR, McCulloch JA, Wang H, Hartman DJ, Badger JH, Fernandes MR, Bai Y, Sun J, Cole AM, Aggarwal P, Fang JR, Deitrick C, Bao R, Duvvuri U, Sridharan SS, Kim SW, A Choudry H, Holtzman MP, Pingpank JF, O'Toole JP, DeBlasio R, Jin Y, Ding Q, Gao W, Groetsch C, Pagliano O, Rose A, Urban C, Singh J, Divarkar P, Mauro D, Bobilev D, Wooldridge J, Krieg AM, Fury MG, Whiteaker JR, Zhao L, Paulovich AG, Najjar YG, Luke JJ, Kirkwood JM, Taube JM, Park HJ, Trinchieri G, Zarour HM. Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial. Cancer Cell. 2024 Nov 11; 42(11):1898-1918.e12.

View in: PubMed

People

Explore

Similar Concepts

Top Journals